全文获取类型
收费全文 | 3536篇 |
免费 | 201篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 55篇 |
妇产科学 | 23篇 |
基础医学 | 493篇 |
口腔科学 | 92篇 |
临床医学 | 244篇 |
内科学 | 1004篇 |
皮肤病学 | 86篇 |
神经病学 | 229篇 |
特种医学 | 161篇 |
外科学 | 516篇 |
综合类 | 6篇 |
预防医学 | 55篇 |
眼科学 | 78篇 |
药学 | 184篇 |
中国医学 | 10篇 |
肿瘤学 | 508篇 |
出版年
2023年 | 33篇 |
2022年 | 19篇 |
2021年 | 135篇 |
2020年 | 70篇 |
2019年 | 112篇 |
2018年 | 105篇 |
2017年 | 84篇 |
2016年 | 119篇 |
2015年 | 109篇 |
2014年 | 132篇 |
2013年 | 170篇 |
2012年 | 243篇 |
2011年 | 242篇 |
2010年 | 178篇 |
2009年 | 120篇 |
2008年 | 204篇 |
2007年 | 227篇 |
2006年 | 211篇 |
2005年 | 207篇 |
2004年 | 198篇 |
2003年 | 183篇 |
2002年 | 211篇 |
2001年 | 44篇 |
2000年 | 34篇 |
1999年 | 35篇 |
1998年 | 34篇 |
1997年 | 33篇 |
1996年 | 29篇 |
1995年 | 23篇 |
1994年 | 28篇 |
1993年 | 24篇 |
1992年 | 18篇 |
1991年 | 11篇 |
1990年 | 9篇 |
1989年 | 15篇 |
1988年 | 8篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1973年 | 4篇 |
排序方式: 共有3764条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Naoko Shoji Keiji Tanese Ayano Sasaki Taishi Horiuchi Yuji Utsuno Koichi Fukuda Yukiko Hoshino Shinichi Noda Hirofumi Minami Wataru Asakura Amenamevir Review Team 《The Journal of dermatology》2020,47(7):683-688
In July 2017, Japan’s Ministry of Health, Labor and Welfare issued a marketing authorization valid throughout Japan for N-(2,6-dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide (amenamevir) for the first time worldwide. The decision was based on the favorable opinion of the Pharmaceuticals and Medical Device Agency (PMDA) recommending a marketing authorization of amenamevir for treatment of herpes zoster (HZ). Amenamevir has a different action mechanism from previously approved synthetic nucleoside compounds for the treatment of HZ including acyclovir, valacyclovir and famciclovir. The usual adult dose is 400 mg amenamevir p.o. once daily for 7 days. The benefit is its ability to cure HZ as well as preventing postherpetic neuralgia. The most common side-effects are increase of urine N-acetyl-β-D-glucosaminidase and α1-microglobulin levels. However, based on the detailed evaluation of the submitted clinical studies, there seems to be no serious safety concerns about amenamevir regarding the kidney of both renally normal and impaired patients. The objective of this article is to summarize the scientific review of the application. The detailed scientific assessment report and product information, including the summary of product characteristics, are available on the PMDA website ( www.pmda.go.jp/PmdaSearch/iyakuSearch/ ). 相似文献
6.
7.
8.
Christina Andica Koji Kamagata Taku Hatano Yuya Saito Wataru Uchida Takashi Ogawa Haruka Takeshige-Amano Akifumi Hagiwara Syo Murata Genko Oyama Yashushi Shimo Atsushi Umemura Toshiaki Akashi Akihiko Wada Kanako K. Kumamaru Masaaki Hori Nobutaka Hattori Shigeki Aoki 《Journal of neuroscience research》2020,98(5):936-949
Neurocognitive and psychiatric disorders have significant consequences for quality of life in patients with Parkinson's disease (PD). In the current study, we evaluated microstructural white matter (WM) alterations associated with neurocognitive and psychiatric disorders in PD using neurite orientation dispersion and density imaging (NODDI) and linked independent component analysis (LICA). The indices of NODDI were compared between 20 and 19 patients with PD with and without neurocognitive and psychiatric disorders, respectively, and 25 healthy controls using tract-based spatial statistics and tract-of-interest analyses. LICA was applied to model inter-subject variability across measures. A widespread reduction in axonal density (indexed by intracellular volume fraction [ICVF]) was demonstrated in PD patients with and without neurocognitive and psychiatric disorders, as compared with healthy controls. Compared with patients without neurocognitive and psychiatric disorders, patients with neurocognitive and psychiatric disorders exhibited more extensive (posterior predominant) decreases in axonal density. Using LICA, ICVF demonstrated the highest contribution (59% weight) to the main effects of diagnosis that reflected widespread decreases in axonal density. These findings suggest that axonal loss is a major factor underlying WM pathology related to neurocognitive and psychiatric disorders in PD, whereas patients with neurocognitive and psychiatric disorders had broader axonal pathology, as compared with those without. LICA suggested that the ICVF can be used as a useful biomarker of microstructural changes in the WM related to neurocognitive and psychiatric disorders in PD. 相似文献
9.
10.